CRISPR Biotech Caribou Trims Pipeline and Cuts 32% of Staff to Focus on Two Cancer Cell Therapies

**Caribou Biosciences Reduces Workforce by 32% and Refocuses on Two Blood Cancer Therapies**

Caribou Biosciences has announced a restructuring plan that will narrow its focus to two cell therapies targeting blood cancers. The company, which specializes in CRISPR gene-editing technology, revealed that this decision includes cutting 32% of its workforce and streamlining its pipeline. Key data readouts for the therapies have been rescheduled to the second half of 2025. This marks Caribou’s second cost-saving restructuring effort within the past year.

The biotech firm aims to prioritize development of “off-the-shelf” cell therapies designed to treat blood cancers, leveraging CRISPR technology for precision editing. By concentrating resources on these two programs, Caribou intends to optimize operations while addressing financial constraints. The company has not disclosed further details about the specific therapies or how the workforce reduction will impact ongoing projects outside of this narrowed scope.

Newsflash | Powered by GeneOnline AI

Source: https://medcitynews.com/2025/04/crispr-biotech-caribou-biosciences-restructuring-cancer-cell-therapy-crbu/

Author

Mark Chiang